2014
DOI: 10.1016/j.ygyno.2014.03.014
|View full text |Cite
|
Sign up to set email alerts
|

Cost-effectiveness of prophylaxis treatment strategies for febrile neutropenia in patients with recurrent ovarian cancer

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

1
6
0

Year Published

2014
2014
2019
2019

Publication Types

Select...
6

Relationship

2
4

Authors

Journals

citations
Cited by 9 publications
(7 citation statements)
references
References 34 publications
1
6
0
Order By: Relevance
“…The models incorporated three sets of data. Clinical data, such as health state transition probabilities, were obtained from Bondarenko et al and other published studies (Bodey et al, 1966 ; Leonard et al, 2003 ; Kuderer et al, 2006 ; Chirivella et al, 2009 ; Freifeld et al, 2011 ; Whyte et al, 2011 ; Fust et al, 2014 ; Wang et al, 2015 ). Transition probabilities and resource use data pertaining to treatment guidelines and clinical practice in a Belgian health care setting were validated or adjusted by Belgian clinicians in a modified Delphi survey.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The models incorporated three sets of data. Clinical data, such as health state transition probabilities, were obtained from Bondarenko et al and other published studies (Bodey et al, 1966 ; Leonard et al, 2003 ; Kuderer et al, 2006 ; Chirivella et al, 2009 ; Freifeld et al, 2011 ; Whyte et al, 2011 ; Fust et al, 2014 ; Wang et al, 2015 ). Transition probabilities and resource use data pertaining to treatment guidelines and clinical practice in a Belgian health care setting were validated or adjusted by Belgian clinicians in a modified Delphi survey.…”
Section: Methodsmentioning
confidence: 99%
“…The perspective taken was that of the Belgian third-party payer (the National Institute for Health and Disability Insurance–INAMI/RIZIV) over a lifetime horizon. In contrast to current economic evaluations comparing G-CSF vs. non-G-CSFs or long-acting G-CSF (e.g., pegfilgrastim) vs. short-acting G-CSF (e.g., filgrastim) that solely track FN events during chemotherapy cycles (Lyman et al, 2009 ; Whyte et al, 2011 ; Fust et al, 2014 , 2015 ; Kulikov et al, 2016 ), the approach taken in this study broadens the scope to additional CIN complications including incidence of SN, infection and chemotherapy dose delay. These are clinically meaningful outcomes considered in clinical guidelines, health technology appraisals and pharmacoeconomic studies (Aapro et al, 2006 ; Rutkowski et al, 2010 ; SMC.…”
Section: Introductionmentioning
confidence: 96%
“…The model structure was adapted from previously published cost-effectiveness models in FN [12, 1416] and includes clinically relevant elements (e.g., FN-related mortality and RDI) that are reflective of real-world clinical observations and practice. Both clinical and modeling experts were consulted during the model development process.…”
Section: Methodsmentioning
confidence: 99%
“…2.2.1–2.2.6. We also used data sources consistent with previously published cost-effectiveness models of FN [12, 1416]. …”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation